Mexico Compared with Thirteen Medical Device Markets

1. Key takeaways

Compared with other markets that Chinese manufacturers have already entered, Mexico shows three structural differences: it adopts a three-tier risk classification (Class I–III, with no fourth class), the sanitary registration is recorded in the name of a Mexican local legal entity, and the statutory obligation for the tecnovigilancia unit falls on the registration holder. In addition, Mexico completed four reforms in a concentrated effort across 2025–2026: the simplified pathway, the restructuring of the low-risk list, and the replacement of the GMP and labelling standards.

• Mexico classifies devices in three tiers, unlike most Asian markets that use four.
• The registration must be held by a Mexican legal entity, which makes holder selection a structural decision.
• The tecnovigilancia duty rests on the holder under NOM-240 Article 6.7.1.
• Four reforms landed between 2025 and 2026, changing pathways, lists, GMP, and labelling.
• System evidence such as MDSAP can be reused across several of the thirteen markets compared here.

2. Legal basis

The comparison below places Mexico beside the thirteen markets that Chinese manufacturers most frequently combine with it. For each market, the competent authority, the core legislation, and the classification tiers are listed. The Mexican row reflects the instruments discussed throughout this section, and the other rows are drawn from each market’s own framework as referenced here.

3. Expert insights

Comparison points across the thirteen markets (practical estimate compilation; each market governs under its own rules)

Insight one: Mexico is the second largest device market in Latin America, but the pace of entry is controlled at the registration stage. Since the simplified pathway went live, companies holding approvals from the FDA, CE, Health Canada, and comparable reference authorities can treat Mexico as a priority entry point for a Latin American footprint, provided the reference documents meet the pathway’s requirements.

Insight two: differences in tier numbers affect the dossier structure of multi-market submissions. The three-tier systems of China, the United States, and Mexico rest on different judgement criteria, and conclusions reached under an A–D four-tier market cannot be mapped directly onto Mexico. Classification arguments should be rebuilt for each destination rather than translated.

Insight three: system evidence can be reused across markets. Companies that already hold MDSAP because of Canada can use their audit reports in Mexico as system evidence, and there is no need to build a separate quality system for Mexico alone. This is one of the strongest cost arguments for aligning the quality programme across the thirteen markets.

Insight four: local holding is a common requirement, but the holder’s duties in Mexico are heavier. The tecnovigilancia unit, the labelling intended-use responsibility, and the platform account all bind to the holder, so the selection standard should be set higher than for an ordinary authorised representative. A partner chosen only for price will struggle under the Mexican allocation of duties.

Insight five: Mexico has been the most intense reform environment of 2025–2026. The simplified pathway, the low-risk list, the GMP revision, the labelling revision, and the renewal extension all landed within less than two years, and continued tracking of these changes is necessary rather than optional for anyone with an active Mexico programme.

4. Practical recommendations

• For multi-market submissions, prepare a separate classification argument and holding structure per market instead of copying one package across destinations.
• Prefer reusable system evidence (MDSAP), letting one audit cover the system needs of Canada, the United States, Brazil, and Mexico.
• Set the holder selection standard for Mexico to include both tecnovigilance capability and platform operation capability.
• Make the availability assessment of the simplified pathway the first step of Mexico entry, and schedule products with suitable reference approvals first.
• Maintain a regulatory tracking table covering the thirteen markets and review it quarterly.

5. Verification checklist

• □ Confirmed that Mexico uses three tiers with no fourth class
• □ The holding structure is designed around the Mexican legal entity requirement
• □ Tecnovigilance duties are clearly assigned to the holder
• □ The reuse value of MDSAP as system evidence has been assessed
• □ Availability of the simplified pathway has been assessed
• □ The thirteen-market tracking table has been established

Regulatory information verified as of 28 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Mexican market. Our team manages COFEPRIS registrations and equivalence (equivalencia) reviews, coordinates third-party authorised centre routes, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com